Cardiol Therapeutics (TSE:CRDL)
TSX:CRDL
Want to see TSE:CRDL full AI Analyst Report?
Top Page
Cardiol Therapeutics
(TSX:CRDL)
Select Model
Select Model
Rating:55Neutral
Price Target:
C$2.50
▲(21.36% Upside)
Action:ReiteratedDate:04/09/26
The score is held back primarily by weak financial performance (pre-revenue, sizable losses, and sustained cash burn), partially offset by a low-debt balance sheet. Technicals are a positive contributor with an improving uptrend and constructive momentum, while valuation remains constrained due to negative earnings and no dividend support.
Positive Factors
Minimal leverage / low debt
A near-zero debt profile materially lowers solvency and interest-rate risk for a cash-burning biotech. This conservatively financed capital structure reduces near-term default risk and preserves flexibility to pursue partnerships or raise equity without looming debt maturities over the next several quarters.
Negative Factors
Pre-revenue status and persistent losses
Being pre-revenue means no internal cash generation to fund trials or commercialization. Persistent operating losses create ongoing funding pressure and make the company reliant on external capital or partners, increasing dilution risk and constraining strategic optionality over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Minimal leverage / low debt
A near-zero debt profile materially lowers solvency and interest-rate risk for a cash-burning biotech. This conservatively financed capital structure reduces near-term default risk and preserves flexibility to pursue partnerships or raise equity without looming debt maturities over the next several quarters.
Read all positive factors
Cardiol Therapeutics (CRDL) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$213.68M
Dividend YieldN/A
Average Volume (3M)136.50K
Price to Earnings (P/E)―
Beta (1Y)2.30
Revenue GrowthN/A
EPS Growth24.04%
CountryCA
Employees18
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.07
Shares Outstanding111,872,086
10 Day Avg. Volume86,077
30 Day Avg. Volume136,495
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)6.37
Price to Sales (P/S)0.00
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$11.62Price Target Upside463.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.46
Revenue Forecast (FY)N/A
Cardiol Therapeutics Business Overview & Revenue Model
Company Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is ...
How the Company Makes Money
null...
Cardiol Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
63
Positive
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 78.76K |
| Gross Profit | 0.00 | -373.11K | -248.35K | -219.91K | 78.76K |
| EBITDA | -34.21M | -36.30M | -27.88M | -30.71M | -38.44M |
| Net Income | -33.82M | -36.68M | -28.13M | -11.52M | -24.72M |
Balance Sheet | |||||
| Total Assets | 23.62M | 31.86M | 36.70M | 62.03M | 87.88M |
| Cash, Cash Equivalents and Short-Term Investments | 21.42M | 30.58M | 34.93M | 59.47M | 83.90M |
| Total Debt | 125.52K | 158.53K | 158.53K | 72.87K | 117.58K |
| Total Liabilities | 5.74M | 7.14M | 8.45M | 9.83M | 11.64M |
| Stockholders Equity | 17.88M | 24.73M | 28.25M | 52.20M | 76.24M |
Cash Flow | |||||
| Free Cash Flow | -23.88M | -25.08M | -25.25K | -27.30M | -23.56M |
| Operating Cash Flow | -23.85M | -25.06M | -25.18K | -27.22M | -23.55M |
| Investing Cash Flow | -24.48K | -21.29K | -64.31K | -74.71K | -12.92K |
| Financing Cash Flow | 15.54M | 18.84M | -55.38K | -53.93K | 93.44M |
Cardiol Therapeutics Technical Analysis
Positive
2.06
Price Trends
1.55
Positive
1.47
Positive
1.54
Positive
Market Momentum
0.14
Negative
69.62
Neutral
73.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CRDL, the sentiment is Positive. The current price of 2.06 is above the 20-day moving average (MA) of 1.78, above the 50-day MA of 1.55, and above the 200-day MA of 1.54, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 69.62 is Neutral, neither overbought nor oversold. The STOCH value of 73.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:CRDL.
Cardiol Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | C$467.95M | 10.05 | 24.23% | ― | 53.74% | 131.96% | |
70 Outperform | C$738.20M | -112.09 | -0.45% | ― | 21.22% | -221.59% | |
66 Neutral | C$130.82M | 294.90 | -0.52% | ― | -7.44% | -108.29% | |
55 Neutral | C$213.68M | -3.37 | -238.02% | ― | ― | 24.04% | |
55 Neutral | C$2.85B | 16.11 | -20.27% | ― | 8.66% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | C$9.91M | -1.68 | -18.39% | ― | 31.72% | -582.73% |
* Healthcare Sector Average
TSE:CRDL
Cardiol Therapeutics
1.86
0.27
16.98%
TSE:BHC
Bausch Health Companies
7.77
0.17
2.24%
TSE:GUD
Knight Therapeutics
7.38
1.39
23.21%
TSE:CPH
Cipher Pharmaceuticals
18.28
4.90
36.62%
TSE:MPH
Medicure
0.95
0.00
0.00%
TSE:MDP
Medexus Pharmaceuticals Inc
3.95
1.14
40.57%
Cardiol Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Cardiol Therapeutics Raises $14.85 Million in Bought-Deal Financing to Support Late-Stage Heart Disease Programs
Positive
Jan 23, 2026
Cardiol Therapeutics has closed a bought-deal private placement of 11,423,078 units at $1.30 per unit, including full exercise of the over-allotment option, raising gross proceeds of $14.85 million. Each unit comprises one common share and one-hal...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.